The Company has a resource-efficient structure, operating through an extensive network of research, development
and manufacturing subcontractors to develop drug candidates through clinical Phase I/II. Clavis Pharma presently has 26 employees
and more than 200 external collaborators worldwide.
External collaborators include front line research institutes and universities such as National Institutes of Health (NIH) and National Cancer
Institute (NCI) and The European Organisation for Research and Treatment
of Cancer (EORTC).